Antiarrhythmic drug therapy (Part 1). Benefits and hazards.
Podrid
P J
PJ
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000145:classification / Q000188:drug therapy*; D001949:Bretylium Compounds / Q000009:adverse effects / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D004206:Disopyramide / Q000009:adverse effects / Q000627:therapeutic use; D004562:Electrocardiography; D004594:Electrophysiology; D006321:Heart / Q000187:drug effects; D006801:Humans; D008012:Lidocaine / Q000009:adverse effects / Q000627:therapeutic use; D011342:Procainamide / Q000009:adverse effects / Q000627:therapeutic use; D011802:Quinidine / Q000009:adverse effects / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D002121:Calcium Channel Blockers; D008012:Lidocaine; D004206:Disopyramide; D011802:Quinidine; D011342:Procainamide; C045166:bretylium